[{"id":"694735df-ac85-49ba-93fc-bc6caa6ca10b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05868174","created_at":"2023-05-22T16:05:29.186Z","updated_at":"2025-02-25T16:18:49.188Z","phase":"Phase 1","brief_title":"Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors","source_id_and_acronym":"NCT05868174","lead_sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","biomarkers":" CA9","pipe":"","alterations":" ","tags":["CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e peposertib (M3814) • 177Lu-DOTA-girentuximab (TLX250) • Rencarex (girentuximab)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 05/23/2023","start_date":" 05/23/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-01"},{"id":"9616c2d2-5400-434d-9a4a-0bdbdb7663da","acronym":"PERTINENCE","url":"https://clinicaltrials.gov/study/NCT04897763","created_at":"2021-05-24T16:53:38.292Z","updated_at":"2024-07-02T16:35:55.050Z","phase":"Phase 1","brief_title":"Assessment of safEty, Tolerability, Radiation Dosimetry, and Imaging Properties of 89Zr-labeled giRenTuximab (89Zr-Girentuximab) in patIents With Non-musclE-iNvasive Bladder CancEr (NMIBC)","source_id_and_acronym":"NCT04897763 - PERTINENCE","lead_sponsor":"Institut Cancerologie de l'Ouest","biomarkers":" CA9","pipe":" | ","alterations":" CA9 expression","tags":["CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CA9 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rencarex (girentuximab)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 08/24/2022","primary_completion_date":" 08/24/2022","study_txt":" Completion: 09/26/2022","study_completion_date":" 09/26/2022","last_update_posted":"2023-02-21"},{"id":"9f6aadae-4c02-4885-9474-ee02d40d74f7","acronym":"OPALESCENCE","url":"https://clinicaltrials.gov/study/NCT04758780","created_at":"2021-02-17T14:01:01.787Z","updated_at":"2024-07-02T16:35:55.082Z","phase":"Phase 2","brief_title":"Imaging Performance Assessment of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in Metastatic Triple Negative Breast Cancer Patients","source_id_and_acronym":"NCT04758780 - OPALESCENCE","lead_sponsor":"Institut Cancerologie de l'Ouest","biomarkers":" HER-2 • ER • PGR • CA9","pipe":" | ","alterations":" CA9 expression","tags":["HER-2 • ER • PGR • CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CA9 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rencarex (girentuximab)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 09/21/2021","start_date":" 09/21/2021","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-02-21"},{"id":"59147de9-a288-4465-b490-08d521c36c94","acronym":"ZIRDAC-JP","url":"https://clinicaltrials.gov/study/NCT04496089","created_at":"2021-01-18T21:35:36.413Z","updated_at":"2024-07-02T16:36:25.928Z","phase":"Phase 1","brief_title":"Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC","source_id_and_acronym":"NCT04496089 - ZIRDAC-JP","lead_sponsor":"Telix International Pty Ltd","biomarkers":" CA9","pipe":" | ","alterations":" CA9 expression","tags":["CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CA9 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rencarex (girentuximab)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 08/01/2020","start_date":" 08/01/2020","primary_txt":" Primary completion: 10/27/2020","primary_completion_date":" 10/27/2020","study_txt":" Completion: 04/06/2021","study_completion_date":" 04/06/2021","last_update_posted":"2021-08-24"},{"id":"9ccb79fc-ad6a-4a61-8273-9ffc47d90e09","acronym":"Zip Up","url":"https://clinicaltrials.gov/study/NCT05018442","created_at":"2021-08-24T11:52:55.186Z","updated_at":"2024-07-02T16:36:25.944Z","phase":"Phase 1/2","brief_title":"89Zr-girentuximab PET in Urothelial Cancer Patients","source_id_and_acronym":"NCT05018442 - Zip Up","lead_sponsor":"Telix International Pty Ltd","biomarkers":" CA9","pipe":"","alterations":" ","tags":["CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rencarex (girentuximab)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 08/03/2021","start_date":" 08/03/2021","primary_txt":" Primary completion: 02/28/2022","primary_completion_date":" 02/28/2022","study_txt":" Completion: 05/31/2022","study_completion_date":" 05/31/2022","last_update_posted":"2021-08-24"},{"id":"ba768302-dd29-4250-bc83-4b97e5814f45","acronym":"","url":"https://clinicaltrials.gov/study/NCT00087022","created_at":"2021-01-18T00:15:20.219Z","updated_at":"2024-07-02T16:37:05.048Z","phase":"Phase 3","brief_title":"Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer","source_id_and_acronym":"NCT00087022","lead_sponsor":"Heidelberg Pharma AG","biomarkers":" CA9","pipe":"","alterations":" ","tags":["CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rencarex (girentuximab)"],"overall_status":"Completed","enrollment":" Enrollment 864","initiation":"Initiation: 07/01/2004","start_date":" 07/01/2004","primary_txt":" Primary completion: 10/01/2012","primary_completion_date":" 10/01/2012","study_txt":" Completion: 10/01/2012","study_completion_date":" 10/01/2012","last_update_posted":"2018-11-27"}]